Metabolic Profiling Reveals Potential Prognostic Biomarkers for SFTS: Insights into Disease Severity and Clinical Outcomes
Metabolites · 27.03.2025 · 15 (4) · 228
DOI: 10.3390/metabo15040228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 27.03.2025. Verfasst von Zhuo-Min Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering and Health, Wuhan Textile University, Wuhan 430200, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University.
Abstract (Originalsprache)
Background/Objectives: Severe fever with thrombocytopenia syndrome (SFTS) is a viral infection primarily found in Asia, with a case fatality rate of about 10%. Despite its increasing prevalence, the underlying pathogenic mechanisms remain poorly understood, limiting the development of effective therapeutic interventions.
Methods
We employed an untargeted metabolomics approach using liquid chromatography–mass spectrometry (LC-MS) to analyze serum samples from 78 SFTS patients during the acute phase of their illness. Differential metabolic features between survival and fatal cases were identified through multivariate statistical analysis. Furthermore, we constructed a metabolic prognostic model based on these biomarkers to predict disease severity.
Results
Significant alterations were observed in four key metabolic pathways: sphingolipid metabolism, biosynthesis of phenylalanine, tyrosine, and tryptophan, primary bile acid biosynthesis, and phenylalanine metabolism. Elevated levels of phenyllactic acid and isocitric acid were strongly associated with adverse outcomes and demonstrated high discriminatory power in distinguishing fatal cases from survivors. The metabolic prognostic model incorporating these biomarkers achieved a sensitivity of 75% and a specificity of 90% in predicting disease severity.
Conclusions
Our findings highlight the pivotal role of metabolic dysregulation in the pathogenesis of SFTS and suggest that targeting specific metabolic pathways could open new avenues for therapeutic development. The identification of prognostic biomarkers provides a valuable tool for early risk stratification and timely clinical intervention, potentially improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Bioengineering and Health, Wuhan Textile University, Wuhan 430200, China.
- School of Public Health, Wuhan University, Wuhan 430072, China.
- Department of Clinical Laboratory, Center for Gene Diagnosis & Program of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Clinical Laboratory, Ezhou Hospital of Traditional Chinese Medicine, Ezhou 436000, China.
- Hubei Province Key Laboratory of Allergy and Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
ORCID-Profile: Quan-Fei Zhu, Yu-Qi Feng
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University
- Open Bidding for Selecting the Best Candidates Project of Wuhan East Lake Hi-tech Development Zone
Zitieren
APA
Zhu, Z. M., Liu, H. Y., An, N., Li, A. L., Li, J., Wang, S. J., Yang, G., Duan, Y. W., Yang, Y., Zhang, M., Zhu, Q. F., Liu, S. M., & Feng, Y. Q. (2025). Metabolic Profiling Reveals Potential Prognostic Biomarkers for SFTS: Insights into Disease Severity and Clinical Outcomes. Metabolites, 15(4), 228. https://doi.org/10.3390/metabo15040228
Vancouver
Zhu ZM, Liu HY, An N, Li AL, Li J, Wang SJ, et al. Metabolic Profiling Reveals Potential Prognostic Biomarkers for SFTS: Insights into Disease Severity and Clinical Outcomes. Metabolites. 2025;15(4):228. doi:10.3390/metabo15040228
BibTeX
@article{Zhu2025,
author = {Zhu, Zhuo-Min and Liu, Huan-Yu and An, Na and Li, An-Ling and Li, Jia and Wang, Sai-Jun and Yang, Gui and Duan, Yong-Wei and Yang, Ying and Zhang, Mei and Zhu, Quan-Fei and Liu, Song-Mei and Feng, Yu-Qi},
title = {Metabolic Profiling Reveals Potential Prognostic Biomarkers for SFTS: Insights into Disease Severity and Clinical Outcomes},
journal = {Metabolites},
year = {2025},
volume = {15},
number = {4},
pages = {228},
doi = {10.3390/metabo15040228}
}
EUVIMED